Matches in Nanopublications for { ?s ?p ?o <http://rdf.disgenet.org/nanopublications.trig#NP250959.RAc9_FazIzmh2v-XPJ8heQ1_N1hOOM_516_iisg-bPHf4130_provenance>. }
Showing items 1 to 9 of
9
with 100 items per page.
- source_evidence_literature type ECO_0000212 NP250959.RAc9_FazIzmh2v-XPJ8heQ1_N1hOOM_516_iisg-bPHf4130_provenance.
- source_evidence_literature label "DisGeNET evidence - LITERATURE" NP250959.RAc9_FazIzmh2v-XPJ8heQ1_N1hOOM_516_iisg-bPHf4130_provenance.
- source_evidence_literature comment "Gene-disease associations inferred from text-mining the literature." NP250959.RAc9_FazIzmh2v-XPJ8heQ1_N1hOOM_516_iisg-bPHf4130_provenance.
- NP250959.RAc9_FazIzmh2v-XPJ8heQ1_N1hOOM_516_iisg-bPHf4130_assertion description "[The ratio of MT-MMP mRNA levels in tumor/normal tissues (T/N ratio) was 3.19 +/- 1.62 in 29 cases of adenocarcinoma, 3.09 +/- 1.44 in 24 cases of squamous cell carcinoma, 4.40 +/- 0.47 in 3 cases of large cell carcinoma and 3.63 +/- 2.11 in 2 cases of small cell carcinoma, respectively.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP250959.RAc9_FazIzmh2v-XPJ8heQ1_N1hOOM_516_iisg-bPHf4130_provenance.
- NP250959.RAc9_FazIzmh2v-XPJ8heQ1_N1hOOM_516_iisg-bPHf4130_assertion evidence source_evidence_literature NP250959.RAc9_FazIzmh2v-XPJ8heQ1_N1hOOM_516_iisg-bPHf4130_provenance.
- NP250959.RAc9_FazIzmh2v-XPJ8heQ1_N1hOOM_516_iisg-bPHf4130_assertion SIO_000772 7591310 NP250959.RAc9_FazIzmh2v-XPJ8heQ1_N1hOOM_516_iisg-bPHf4130_provenance.
- NP250959.RAc9_FazIzmh2v-XPJ8heQ1_N1hOOM_516_iisg-bPHf4130_assertion wasDerivedFrom befree-20140225 NP250959.RAc9_FazIzmh2v-XPJ8heQ1_N1hOOM_516_iisg-bPHf4130_provenance.
- NP250959.RAc9_FazIzmh2v-XPJ8heQ1_N1hOOM_516_iisg-bPHf4130_assertion wasGeneratedBy ECO_0000203 NP250959.RAc9_FazIzmh2v-XPJ8heQ1_N1hOOM_516_iisg-bPHf4130_provenance.
- befree-20140225 importedOn "2014-02-25" NP250959.RAc9_FazIzmh2v-XPJ8heQ1_N1hOOM_516_iisg-bPHf4130_provenance.